Clinical Trial Update: Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating iparomlimab and tuvonralimab in combination with 2 or 4 cycles of chemotherapy as neoadjuvant therapy for resectable non-small…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: NOT_YET_RECRUITING